Safety Evaluation of Allogeneic Umbilical Cord Blood Mononuclear Cell Therapy

If I am understanding this study correctly, the researchers tested the safety of allogeneic cord blood in patients without immunosuppression. The results indicate that no graft versus host disease or serious adverse events were exhibited.

Here is some information about the study:

Methods

114 patients suffering from non-hematopoietic degenerative conditions were treated with non-matched, allogeneic cord blood. Doses of 1-3 × 10⁷ cord blood mononuclear cells per treatment, with 4-5 treatments both intrathecal and intravenously were performed. Adverse events and hematological, immunological, and biochemical parameters were analyzed for safety evaluation.

Results

No serious adverse effects were reported. Hematological, immunological, and biochemical parameters did not deviate from normal ranges as a result of therapy.

Conclusion

The current hematology-based paradigm of need for matching and immune suppression needs to be revisited when cord blood is used for non-hematopoietic regenerative purposes in immune competent recipients.

More information can be found at the Journal of Translational Medicine.